PEN241220P440000
- 0.00
- 0.000.00%
Penumbra Newsroom
Penumbra Is Maintained at Buy by BTIG
International Expansion Supports BSX Stock Amid Macroeconomic Woes
BTIG Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $270
Cautious Hold Recommendation Amid Uncertainty Following FDA Clearance of Penumbra's Element Vascular Access System
Penumbra, Inc. (PEN): Innovating in Thrombectomy and Embolization With New FDA-Approved Technologies
Express News | Penumbra Inc : Leerink Partners Raises Target Price to $262 From $240
Insider Sale: CEO and President of $PEN (PEN) Sells 3,281 Shares
Penumbra(PEN.US) Officer Sells US$3.56 Million in Common Stock
PODD Stock to Gain From Launch of Omnipod 5 With Abbott's CGM in US
Penumbra's Prospective Growth Amidst Market Dynamics Justifies Hold Rating
3 Reasons Growth Investors Will Love Penumbra (PEN)
Form 144 | Penumbra(PEN.US) Insider Proposes to Sell 7.11 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 20, $Penumbra(PEN.US)$ Insider Adam Elsesser intends to sell 30,000 shares of its common stock on Nov 20, with a total market value of approximately $7.11 million. Adam
Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference
Breaking Down Penumbra: 11 Analysts Share Their Views
Penumbra Is Maintained at Overweight by Piper Sandler
Penumbra Analyst Ratings
Piper Sandler Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $250
Express News | Penumbra Inc : Piper Sandler Raises Target Price to $250 From $235
Here's Why You Should Add OMCL Stock to Your Portfolio Now
Penumbra, Inc. (PEN): A Bull Case Theory